| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | bafilomycin A1 | CTRPv2 | pan-cancer | AAC | 0.52 | 3e-05 |
| mRNA | XMD13-2 | GDSC1000 | pan-cancer | AAC | 0.099 | 0.001 |
| mRNA | apicidin | CTRPv2 | pan-cancer | AAC | -0.094 | 0.002 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.089 | 0.003 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.005 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.085 | 0.01 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | Pyrimethamine | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |